Hong J, Liu W, Xiao X, Gajendran B, Ben-David Y
Heliyon. 2024; 10(23):e40492.
PMID: 39654725
PMC: 11626780.
DOI: 10.1016/j.heliyon.2024.e40492.
Niscola P, Gianfelici V, Catalano G, Giovannini M, Mazzone C, Noguera N
Curr Oncol. 2024; 31(11):6632-6658.
PMID: 39590121
PMC: 11592437.
DOI: 10.3390/curroncol31110490.
Guo J, Buettner R, Du L, Li Z, Liu W, Su R
Leukemia. 2024; 38(6):1236-1245.
PMID: 38643304
PMC: 11147765.
DOI: 10.1038/s41375-024-02222-w.
Valdez B, Yuan B, Murray D, Ramdial J, Popat U, Nieto Y
Oncotarget. 2024; 15:220-231.
PMID: 38484153
PMC: 10939475.
DOI: 10.18632/oncotarget.28563.
Xu X, Yu Y, Zhang W, Ma W, He C, Qiu G
Nat Cell Biol. 2024; 26(3):464-477.
PMID: 38321204
DOI: 10.1038/s41556-024-01349-3.
Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer.
Liu C, Chen L, Cai Y, Chen Y, Liu Y, Zhou Y
Cell Rep Med. 2024; 5(2):101396.
PMID: 38290515
PMC: 10897545.
DOI: 10.1016/j.xcrm.2024.101396.
Hexamethylene amiloride synergizes with venetoclax to induce lysosome-dependent cell death in acute myeloid leukemia.
Jiang X, Huang K, Sun X, Li Y, Hua L, Liu F
iScience. 2024; 27(1):108691.
PMID: 38205254
PMC: 10776932.
DOI: 10.1016/j.isci.2023.108691.
Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia.
Huang W, Zheng S, Wang Q, Zhao N, Long Z
Sci Rep. 2023; 13(1):15658.
PMID: 37730831
PMC: 10511414.
DOI: 10.1038/s41598-023-42700-2.
Glucose partitioning in the bone marrow micro-environment in acute myeloid leukaemia.
Deng S, Du J, Gale R, Wang L, Zhan H, Liu F
Leukemia. 2023; 37(7):1407-1412.
PMID: 37120691
DOI: 10.1038/s41375-023-01912-1.
Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment.
Tabe Y, Konopleva M
Cancer Drug Resist. 2023; 6(1):138-150.
PMID: 37065866
PMC: 10099600.
DOI: 10.20517/cdr.2022.133.
Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions.
Zhao H, Deininger M
Blood. 2023; 141(23):2797-2812.
PMID: 36947811
PMC: 10315634.
DOI: 10.1182/blood.2022017152.
Lipid profile as a novel prognostic predictor for patients with acute myeloid leukemia.
Bai S, Wang H, Shao R, Fu B, Lu S, Wang J
Front Oncol. 2023; 13:950732.
PMID: 36798819
PMC: 9927215.
DOI: 10.3389/fonc.2023.950732.
Novel insight into metabolic reprogrammming in cancer radioresistance: A promising therapeutic target in radiotherapy.
Yu Y, Yu J, Ge S, Su Y, Fan X
Int J Biol Sci. 2023; 19(3):811-828.
PMID: 36778122
PMC: 9910008.
DOI: 10.7150/ijbs.79928.
The mA reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia.
Weng H, Huang F, Yu Z, Chen Z, Prince E, Kang Y
Cancer Cell. 2022; 40(12):1566-1582.e10.
PMID: 36306790
PMC: 9772162.
DOI: 10.1016/j.ccell.2022.10.004.
A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia.
Zhang H, Sun Z, Zhong F, Yao F, Liu J, Zhang J
Lipids Health Dis. 2022; 21(1):79.
PMID: 36002858
PMC: 9404605.
DOI: 10.1186/s12944-022-01687-x.
Development and Validation of an Individualized Metabolism-Related Prognostic Model for Adult Acute Myeloid Leukemia Patients.
Wei C, Ding L, Luo Q, Li X, Zeng X, Kong D
Front Oncol. 2022; 12:829007.
PMID: 35785164
PMC: 9247176.
DOI: 10.3389/fonc.2022.829007.
The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness.
Thomas G, Egan G, Garcia-Prat L, Botham A, Voisin V, Patel P
Nat Cell Biol. 2022; 24(6):872-884.
PMID: 35668135
PMC: 9203277.
DOI: 10.1038/s41556-022-00925-9.
Targeting Mitochondrial Oxidative Phosphorylation Eradicates Acute Myeloid Leukemic Stem Cells.
Peng M, Huang Y, Zhang L, Zhao X, Hou Y
Front Oncol. 2022; 12:899502.
PMID: 35574326
PMC: 9100571.
DOI: 10.3389/fonc.2022.899502.
Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?.
Ciciarello M, Corradi G, Forte D, Cavo M, Curti A
Cancers (Basel). 2021; 13(21).
PMID: 34771483
PMC: 8582363.
DOI: 10.3390/cancers13215319.
SLC1A5 provides glutamine and asparagine necessary for bone development in mice.
Sharma D, Yu Y, Shen L, Zhang G, Karner C
Elife. 2021; 10.
PMID: 34647520
PMC: 8553342.
DOI: 10.7554/eLife.71595.
